ACTG 362: AZITHROMYCIN PROPHYLAXIS FOR PRIMARY PREVENTION OF MAC IN AIDS

ACTG 362：阿奇霉素预防用于艾滋病 MAC 的一级预防

• 批准号: 7605678
• 负责人: JUDITH Ann ABERG
• 金额: $ 1.76万
• 依托单位: NEW YORK UNIVERSITY SCHOOL OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-04-01 至 2008-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7605678
• 关键词: AIDS clinical trial group; Acquired Immunodeficiency Syndrome; Azithromycin; Bacterial Infections; CD4 Positive T Lymphocytes; Cells; Computer Retrieval of Information on Scientific Projects Database; Development; Diagnosis; End Point; Funding; Grant; HIV; Infection; Institution; Mycobacterium avium Complex; Patients; Primary Prevention; Prophylactic treatment; Research; Research Personnel; Resources; Source; Time; United States National Institutes of Health; Week; antiretroviral therapy; randomized placebo controlled trial

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a randomized placebo-controlled study to determine the efficacy of Azithromycin for primary prevention of Mycobacterium Avium Complex (MAC) and other infections in subjects who have acheived an increase in CD4 cells (from < 50 to >100 cells/mm3) on antiretroviral therapy. Subjects may not have had a prior diagnosis of MAC and will receive 1200 mg of Azithromycin once a week. The primary endpoint is to compare the time to development of MAC. There are numerous secondary objectives and several substudies evaluating azithromycin's effect on other bacterial infections common in the HIV+ patient.

这个子项目是众多研究子项目之一